A phase 2, randomized study of Bortezomib/Dexamethasone with or without Elotuzumab in subjects with relapsed/refractory Multiple Myeloma (CA204009)

Service: Trial Number:
061-12
Conducted at:
Long Beach Memorial, Orange Coast Memorial
Currently enrolling additional patients:
Yes
Gender:
Female

This phase 2, multicenter, open-label, randomized study at Long Beach Memorial Medical Center and Orange Coast Memorial Medical Center will assess the effect of bortezomib, dexamethasone, and elotuzumab, (BdE; investigational arm) compared with bortezomib and dexamethasone (Bd; control group) in subjects with relapsed/refractory multiple myeloma (MM).  The study will compare progression-free survival (PFS) between treatment arms in the overall population while also estimating other statistical relevant information in a subgroup with a portion of DNA that is associated with approved clinical response. Each patient will take part in a screening period, when the study doctor will determine eligibility status. If patients are eligible, they will return to the study clinic on Day 1 for additional study assessments before beginning study drug that day.

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.
Address
,
 
The email to associate with this registration.